Photon Fund

Photon Fund is a venture capital firm based in Shenzhen, China, with additional offices in Beijing and Silicon Valley. Established in 2015, the firm specializes in early-stage investments across various sectors, including technology, innovation, media, telecommunications, advanced manufacturing, and new materials. The core team possesses over 20 years of experience in equity investment, focusing on technology, media, and telecommunications, as well as high-end manufacturing. Photon Fund emphasizes a research-driven approach, prioritizing independent judgment and value creation for its portfolio companies. The firm's investment philosophy aims to foster scientific and technological advancement, playing a significant role in promoting innovation within China and on a global scale.

James Lee

Managing Director

Zhenlin Li

Partner

David Wang

Co-Founding General Partner

13 past transactions

Bichen Pharmaceutical

Series B in 2022
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Amplicore

Seed Round in 2021
Developer of injectable therapeutic drugs designed to treat degenerative musculoskeletal disorders to serve unmet medical needs. The company's drugs promote cartilage regeneration and suppress enzymatic activities to treat degenerative musculoskeletal disorders, enabling healthcare organizations to seamlessly provide relief to patients from joint pain.

Newomics

Series B in 2020
Newomics Inc. manufactures biotechnological research equipment. The company offers proprietary technology based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Newomics Inc. was incorporated in 2011 and is based in Berkeley, California.

Cardea

Series A in 2020
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, specializing in bioelectronics and graphene-based digital biosensor technology. Founded in 2013, the company develops products that facilitate precision healthcare by enhancing the ease, speed, and cost-effectiveness of diagnostics. Its key offerings include AGILE R100, an innovative assay for small molecule drug discovery, and AGILE R200, an automated high-throughput screening solution. Cardea's biosensors utilize biocompatible graphene to transform biological signals into digital data, enabling real-time analysis of biomolecules. This technology supports applications in small molecule validation, antibody characterization, and biomolecular analysis, serving the life sciences and healthcare sectors. The company also sells its products online, contributing to advancements in research and diagnostics.

Nelumbo

Series A in 2020
Nelumbo Inc. manufactures thin superomniphobic nanocoating for air conditioning cooling coil fins and refrigerators. The company manufactures products, such as Ice-Nein and Omniphobe. Ice-Nein coating attacks frost build up to improve cooling coils for refrigeration equipment and reduces equipment defrosting downtime; and Omniphobe coating improves cooling coils for air conditioning equipment. The company caters to the heating and cooling industry. Nelumbo Inc. was founded in 2015 and is based in Menlo Park, California.

CASPR Biotech

Convertible Note in 2020
CASPR Biotech is a San Francisco-based company established in 2018 that specializes in developing a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. By offering a simple, fast, and affordable solution, CASPR Biotech aims to assist healthcare providers in delivering efficient diagnostics within clinical and hospital settings.

Valitor

Series A in 2018
Valitor, Inc. is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in developing advanced, protein-based drugs and has established pipelines targeting oncology, dermatology, ophthalmology, and orthopedics. Valitor employs novel methods to modify therapeutic proteins, enhancing their pharmacokinetics, target specificity, and bioactivity. This innovative technology platform aims to improve the pharmacological properties of both existing and emerging protein drugs, allowing for more effective treatment strategies for various diseases. By focusing on targeted therapeutic delivery, Valitor seeks to optimize patient outcomes through its next-generation drug development initiatives.

Newomics

Series A in 2018
Newomics Inc. manufactures biotechnological research equipment. The company offers proprietary technology based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Newomics Inc. was incorporated in 2011 and is based in Berkeley, California.

Nelumbo

Series A in 2018
Nelumbo Inc. manufactures thin superomniphobic nanocoating for air conditioning cooling coil fins and refrigerators. The company manufactures products, such as Ice-Nein and Omniphobe. Ice-Nein coating attacks frost build up to improve cooling coils for refrigeration equipment and reduces equipment defrosting downtime; and Omniphobe coating improves cooling coils for air conditioning equipment. The company caters to the heating and cooling industry. Nelumbo Inc. was founded in 2015 and is based in Menlo Park, California.

CARsgen Therapeutics

Series C in 2018
CARsgen Therapeutics, Ltd., a clinical-stage immunotherapy company, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapeutics for treating cancers. It offers CAR-T Technology that directs T cells to recognize cancer cells based on expression of specific cell surface proteins to treat solid and hematologic tumors. The company’s CAR-T cells target the GPC3 receptor for the treatment of late-stage hepatocellular carcinoma (HCC, or liver cancer) and lung squamous cell carcinoma (a common type of lung cancer). CARsgen Therapeutics, Ltd. is based in Shanghai, China.

Hongliyu Cinema

Series B in 2018
Hongliyu Cinema is a Chinese rural cinema operator. It focuses on film and television production and advertising operation services, and professional support in China.

Techtotop

Series B in 2017
Smart Hardware Company based in Guangzhou,China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.